Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Hemodynamic effects of ephedra-free weight-loss supplements in humans.

Haller CA, Benowitz NL, Jacob P 3rd.

Am J Med. 2005 Sep;118(9):998-1003.

PMID:
16164886
2.

Short-term metabolic and hemodynamic effects of ephedra and guarana combinations.

Haller CA, Jacob P, Benowitz NL.

Clin Pharmacol Ther. 2005 Jun;77(6):560-71.

PMID:
15961987
3.

Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects.

Csajka C, Haller CA, Benowitz NL, Verotta D.

Br J Clin Pharmacol. 2005 Mar;59(3):335-45.

4.

Caffeine induced Ca2+ release and capacitative Ca2+ entry in human embryonic kidney (HEK293) cells.

Luo D, Sun H, Xiao RP, Han Q.

Eur J Pharmacol. 2005 Feb 21;509(2-3):109-15.

PMID:
15733545
5.

Caffeine-herbal ephedra combination increases resting energy expenditure, heart rate and blood pressure.

Vukovich MD, Schoorman R, Heilman C, Jacob P 3rd, Benowitz NL.

Clin Exp Pharmacol Physiol. 2005 Jan-Feb;32(1-2):47-53.

PMID:
15730434
6.

Is there an association between ephedra and heart failure? a case series.

Peters CM, O'Neill JO, Young JB, Bott-Silverman C.

J Card Fail. 2005 Feb;11(1):9-11.

PMID:
15704057
7.

Ephedrine plus caffeine causes age-dependent cardiovascular responses in Fischer 344 rats.

Howden R, Hanlon PR, Petranka JG, Kleeberger S, Bucher J, Dunnick J, Nyska A, Murphy E.

Am J Physiol Heart Circ Physiol. 2005 May;288(5):H2219-24. Epub 2005 Jan 14.

8.

Acute hemorrhagic myocardial necrosis and sudden death of rats exposed to a combination of ephedrine and caffeine.

Nyska A, Murphy E, Foley JF, Collins BJ, Petranka J, Howden R, Hanlon P, Dunnick JK.

Toxicol Sci. 2005 Feb;83(2):388-96. Epub 2004 Nov 10.

9.
10.

Determination of ephedra alkaloid and caffeine concentrations in dietary supplements and biological fluids.

Jacob P 3rd, Haller CA, Duan M, Yu L, Peng M, Benowitz NL.

J Anal Toxicol. 2004 Apr;28(3):152-9.

11.

Concentrations of ephedra alkaloids and caffeine in commercial dietary supplements.

Haller CA, Duan M, Benowitz NL, Jacob P 3rd.

J Anal Toxicol. 2004 Apr;28(3):145-51.

12.

Modelling the cardiovascular effects of ephedrine.

Persky AM, Berry NS, Pollack GM, Brouwer KL.

Br J Clin Pharmacol. 2004 May;57(5):552-62.

13.
14.

Ephedra-associated cardiomyopathy.

Naik SD, Freudenberger RS.

Ann Pharmacother. 2004 Mar;38(3):400-3. Epub 2004 Jan 23.

PMID:
14742827
15.

Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine: a randomized controlled trial.

McBride BF, Karapanos AK, Krudysz A, Kluger J, Coleman CI, White CM.

JAMA. 2004 Jan 14;291(2):216-21.

PMID:
14722148
16.

Noradrenergic modulation of ephedrine-induced hypophagia.

Wellman PJ, Miller DK, Ho DH.

Synapse. 2003 Apr;48(1):18-24.

PMID:
12557268
17.

Pharmacology of ephedra alkaloids and caffeine after single-dose dietary supplement use.

Haller CA, Jacob P 3rd, Benowitz NL.

Clin Pharmacol Ther. 2002 Jun;71(6):421-32.

PMID:
12087345
18.

Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies.

Shackelford C, Long G, Wolf J, Okerberg C, Herbert R.

Toxicol Pathol. 2002 Jan-Feb;30(1):93-6. Review.

19.

Role of the phospholipase C-inositol 1,4,5-trisphosphate pathway in calcium release-activated calcium current and capacitative calcium entry.

Broad LM, Braun FJ, Lievremont JP, Bird GS, Kurosaki T, Putney JW Jr.

J Biol Chem. 2001 May 11;276(19):15945-52. Epub 2001 Feb 13.

20.

Mutual antagonism of calcium entry by capacitative and arachidonic acid-mediated calcium entry pathways.

Luo D, Broad LM, Bird GS, Putney JW Jr.

J Biol Chem. 2001 Jun 8;276(23):20186-9. Epub 2001 Mar 23.

Items per page

Supplemental Content

Write to the Help Desk